Stock XLRN ACCELERON PHARMA INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Acceleron Pharma Inc.

Equities

XLRN

US00434H1086

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Global markets live: Airbus, BP, Merck, Pfizer, Meta...
Our Logo
Bristol Myers Squibb Gets FDA Acceptance of sBLA for Reblozyl
DJ
Acceleron Pharma Inc.(NasdaqGM:XLRN) dropped from NASDAQ Biotechnology Index
CI
Acceleron Pharma : Completion of Acquisition or Disposition of Assets - Form 8-K
PU
ACCELERON PHARMA INC : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)
AQ
Merck Completes Acceleron Pharma Acquisition
MT
Merck Completes Tender Offer to Acquire Acceleron Pharma Inc.
AQ
Merck Completes Cash Tender Offer to Purchase Acceleron Pharma at $180/Share
MT
Acceleron Pharma Inc.(NasdaqGM:XLRN) dropped from NASDAQ Composite Index
CI
Acceleron Pharma Inc.(NasdaqGM:XLRN) dropped from S&P Global BMI Index
CI
Acceleron Pharma Inc.(NasdaqGM:XLRN) dropped from S&P TMI Index
CI
Acceleron Pharma Inc.(NasdaqGM:XLRN) dropped from S&P Biotechnology Select Industry Index
CI
Merck Completes Tender Offer to Acquire Acceleron Pharma Inc
CI
Merck Sharp & Dohme Corp. completed the acquisition of Acceleron Pharma Inc. from Avoro Capital Advisors LLC, Holocene Advisors, LP, Darwin Global Management Limited and others for $7.1 billion.
CI
Avoro Capital Urges Acceleron Shareholders Not to Tender Into Merck's 'Inadequate' Offer
MT
Avoro Capital Urges Acceleron Shareholders Not to Tender Into Merck’s Inadequate Offer
BU
Merck Extends Tender Offer for Acceleron Pharma
MT
Avoro Capital Releases Presentation Detailing Why Acceleron Shareholders Should Not Tender Into Merck’s Inadequate Offer
BU
Acceleron Reports Third Quarter 2021 Financial Results - Form 8-K
PU
Acceleron: Q3 Earnings Snapshot
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. XLRN Stock
  4. News Acceleron Pharma Inc.